title: Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients.
abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. However, treatment options are limited and often inefficient. The aim of this study was to determine current survival rates for patients diagnosed with HCC and to identify prognostic factors, which will help in choosing optimal therapies for individual patients. A retrospective analysis of medical records was performed on 389 patients who were identified through the central tumour registry at our institution from 1998 to 2003. Clinical parameters, treatments received and survival curves from time of diagnosis were analysed. Overall median survival was 11 months. Liver cirrhosis was diagnosed in 80.5% of all patients. A total of 170 patients received transarterial chemoembolisation (TACE) and/or percutaneous ethanol injections (PEI) with a median survival rate of 16 months for patients receiving TACE, 11 months for patients receiving PEI and 24 months for patients receiving TACE followed by PEI. Independent negative prognostic parameters for survival were the presence of portal vein thrombosis, advanced liver cirrhosis (Child-Pugh score B or C) and a score of >2. This study will help to estimate survival rates for patients with HCC according to their clinical status at diagnosis and the treatments received.
authors.affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule, Carl Neuberg Str 1, Hannover 30625, Germany. greten.tim@mh-hannover.de
authors.forename: T F
authors.initials: TF
authors.lastname: Greten
authors.forename: F
authors.initials: F
authors.lastname: Papendorf
authors.forename: J S
authors.initials: JS
authors.lastname: Bleck
authors.forename: T
authors.initials: T
authors.lastname: Kirchhoff
authors.forename: T
authors.initials: T
authors.lastname: Wohlberedt
authors.forename: S
authors.initials: S
authors.lastname: Kubicka
authors.forename: J
authors.initials: J
authors.lastname: Klempnauer
authors.forename: M
authors.initials: M
authors.lastname: Galanski
authors.forename: M P
authors.initials: MP
authors.lastname: Manns
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000473:pathology* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology; D008113:Liver Neoplasms / Q000150:complications / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012042:Registries / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D012997:Solvents / Q000008:administration & dosage / Q000627:therapeutic use; D016019:Survival Analysis; D020246:Venous Thrombosis
chemical_list: D012997:Solvents; D000431:Ethanol